AI-Designed Drug Shows Potential to Slow Aging in Clinical Trial
Insilico Medicine's clinical trial of rentosertib, an AI-designed drug initially aimed at treating chronic lung disease, suggests it may also slow aging by reducing biological age markers measured by six AI-based aging clocks. Published in Nature Biotechnology, the study highlights AI's growing role in drug discovery and longevity research. However, the drug's anti-aging effects remain untested in healthy individuals, and regulatory approval could take years. Scientists continue to debate the reliability of aging clocks as predictors of morbidity and mortality.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (68/100). Lens Score 39/100.
Outlets measured: indianexpress, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (68–68/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 7 Sept, 05:26 pm. Other outlets followed.
- 1